Introduction
BRCA1, the ®rst familial breast and ovarian cancer gene discovered, accounts for approximately 5% of all breast cancer cases (Miki et al., 1994; Cannon-Albright and Skolnick, 1996) . Currently, the mechanisms of tumor suppression by BRCA1 are not well understood. It is plausible that BRCA1 activities are either regulated or mediated by interactions with other cellular proteins. Disruption of these protein-protein interactions by deleterious mutations in BRCA1 could be one signi®cant step in tumorigenesis. A number of BRCA1 interacting proteins have been identi®ed in the past 3 years. For example, BARD1 binds to the RING ®nger near the N-terminus of BRCA1 (Wu et al., 1996) and is mutated in primary breast, ovarian, and uterine cancer (Thai et al., 1998) . The biological function of BARD1 has not been de®ned, though it is thought to play a role in DNA replication checkpoint control (Scully et al., 1997a; Jin et al., 1997) . Certain germline mutations in BRCA1 have been reported to disrupt its interaction with BARD1. BAP1, a nuclear localized ubiquitin carboxy-terminal hydrolase, also binds speci®cally to the BRCA1 RING ®nger region (Jensen et al., 1998 ). An 8 bp deletion of the BAP1 gene was observed in a non-small cell lung carcinoma cell line implicating its role in tumorigenesis. It was shown by colony formation assays that BAP1 can enhance BRCA1-mediated suppression of cell growth (Jensen et al., 1998) . Importin-a, a component of the nuclear localization signal (NLS) receptor complex , and BRAP2, a cytoplasmic protein that binds to the NLS motif (Li et al., 1998) , also associate with the BRCA1 protein. It has been proposed that an aberration in the subcellular localization of BRCA1 in breast tumor cells is a mechanism by which the BRCA1 tumor suppressor function is perturbed (Chen et al., 1995) . However, questions have been raised about the accuracy of the localization data because con¯icting results have been reported by dierent groups (Jensen et al., 1996; Wilson et al., 1997) . RAD51, a homolog to the E. coli Rec A protein that is involved in the repair of double-strand DNA breaks (Shinohara et al., 1992) , is known to interact with BRCA1 (Scully et al., 1997b) , and the second familial breast cancer gene product BRCA2 (Tavtigian et al., 1996; Sharan et al., 1997; Wong et al., 1997) . In BRCA2, the sites of RAD51 interaction have been ®ne-mapped to the eight evolutionarily conserved BRC motifs in the internal region of the protein . However these BRC motifs are not found in BRCA1. It seems likely that a cofactor may mediate binding of RAD51 to BRCA1. Co-localization of BRCA1 with RAD51 in synaptonemal complexes (Scully et al., 1997b) , and hyperphosphorylation of BRCA1 in response to DNA damage (Scully et al., 1997a) suggest that BRCA1 plays roles in both recombination and repair.
BRCA1 appears to be a multifunctional protein. In addition to a possible role in DNA repair, it has been implicated in the control of the cell cycle and cell proliferation (Hakem et al., 1996; Somasundaram et al., 1997) and regulation of transcription in a p53 dependent and independent manner (Somasundaram et al., 1997; Ouchi et al., 1998) . BRCA1 was originally postulated to function as a transcriptional activator when the carboxy-terminal region of BRCA1 fused to a heterologous DNA binding domain showed transcriptional activity (Chapman and Verma, 1996; Monteiro et al., 1996) . Subsequently it was shown that BRCA1 is a component of the transcriptionally active RNA polymerase II holoenzyme complex (Scully et al., 1997c) . Some germline mutations at the carboxyterminal region of BRCA1 are known to abolish transcriptional activation function (Chapman and Verma, 1996; Monteiro et al., 1996) . Coincidentally the Y1853ter mutation that causes a C-terminal truncation of BRCA1 also ablates the interaction of the RNA polymerase II holoenzyme (Scully et al., 1997c) .
We have conducted yeast two hybrid searches using the BRCA1 carboxy-terminal segment as`bait' to identify interacting proteins that could further our understanding of BRCA1 and the pathway in which it is involved. We demonstrate that CtIP is a speci®c BRCA1 interacting protein. CtIP has been identi®ed recently to bind to CtBP, a transcriptional repressor that is suggested to regulate the transforming activity of the adenoviral E1A protein (Boyd et al., 1993; Schaeper et al., 1995) . Deletion of the last 11 residues at the carboxy-terminus of BRCA1 by the previously identi®ed Y1853ter familial mutation abolishes the BRCA1-CtIP interaction.
Results

Identi®cation of BRCA1 interacting protein by yeast two-hybrid assay
In our yeast two-hybrid searches, the carboxy terminus of BRCA1 (residues 1602 ± 1863) as a Gal4p DNA-binding domain fusion was used to search an EBV-transformed human B-cell activation domain cDNA library. One of the His + b-galactosidase colonies, designated as B112, was chosen for further characterization. Because the BRCA1 protein in the Gal4p DNA-binding fusion could weakly selfactivate resulting in background activity of the reporter b-galactosidase, a number of controls were performed to verify that interaction with the B112 protein is speci®c. The inserts from clone B112 and the carboxy-terminal segment of BRCA1 were cloned into Gal4p DNA-binding and activation domain vectors for analysis in all pairwise combinations by co-transformation in yeast. As shown in Table 1 , the interaction of the BRCA1 DNA-binding domain fusion with the B112 activation domain fusion resulted in stronger b-galactosidase activity than the activity that was generated by the BRCA1 DNAbinding domain fusion alone. Placement of BRCA1 in the activation domain vector pGAD.C eliminated selfactivation. Strong b-galactosidase activity was also observed when this construct was cotransformed with B112 in the DNA-binding domain plasmid pGBT.C. As an additional control, the B112 activation domain fusion was tested against a non-speci®c target, lamin C. The yeast transformants harboring these two fusions were negative in the b-galactosidase assay (Table 1 ).
Characterization of clone B112
Next, we investigated the size, tissue distribution, and abundance of B112 RNA. Northern analysis revealed that the B112 mRNA transcript is approximately 3.4 kb in size and is expressed in a variety of tissues including spleen, thymus, prostate, testis, ovary, small intestine, colon and blood leukocyte ( Figure 1a ). Of these eight tissues examined, the highest level of expression was observed in testis followed by thymus. Expression dierences observed for B112 were not due to sample loading variations because the internal control G3PDH mRNA levels were equivalent in all samples ( Figure 1a , bottom panel). We also examined the expression level and size of B112 mRNA in tumor and corresponding normal breast tissues (representative example shown in Figure 1a ). Aberrantly spliced variant or signi®cant variation in expression levels were not detected from this Northern blot analysis. Because the insert in clone B112 was only 1.2 kb, 5' and 3' RACE were performed to obtain the full length gene. We identi®ed an open reading frame of 2694 bp encoding a 897 amino acid polypeptide. Sequence comparison indicated that the B112 gene is nearly identical to the gene known as CtIP (accession number U72066) which was submitted to GenBank while our full length cloning was in progress. For uniformity, the name CtIP is adopted for our BRCA1 interacting protein B112. We found that at nucleotide position 11, the fourth codon of our sequence is TCG, which encodes serine, whereas the original CtIP sequence reports the fourth codon as TTG, which encodes leucine. Our sequence is based on the consensus obtained from sequencing the gene from multiple cDNA sources. Furthermore, we found that two bases in the 5' untranslated region (G at 7131 and T at 7166) and one base in the 3' untranslated region (C at +2939) are not reported in the previously published CtIP sequence. The predicted CtIP translated product is shown in Figure 1b . A search of known consensus motifs has identi®ed several potential nuclear localization signals in the protein sequence beginning at residues 355 (KKKH), 446 (KRKK), 874 (PCPRPKR) and 878 (PKRRQPY).
A germline mutation in BRCA1 disrupts interaction with CtIP
Familial mutations are found in the carboxy-terminal segment of BRCA1. One of these mutations, Y1853ter, introduces a stop codon that removes the last 11 amino acid residues of the wild type protein. To determine whether the Y1853ter mutation could perturb the interaction of BRCA1 with CtIP, a BRCA1 fragment without the last 11 amino acids was generated by PCR and cloned into the Gal4p DNA binding domain and activation domain vectors. The wild type and mutant BRCA1 carboxy terminal fusion constructs were cotransformed with CtIP-Gal4p fusion constructs in yeast. As shown in Table 1 , the mutant, 1853ter-BRCA1, did not interact with CtIP expressed either as a Gal4p-DNA binding or activation domain fusion. We also found that the removal of the 11 amino acid residues abolished the weak self-activation phenotype of BRCA1 in the Gal4p DNA binding domain vector as b-galactosidase activity was not observed in these transformants.
In vitro protein-protein interaction assay of mutant and wild type BRCA1 with CtIP
The GST-anity pull down assay is a complementary in vitro method for con®rming the yeast two hybrid protein-protein interactions. To ascertain that the interaction between BRCA1 and the CtIP protein was direct and to show that the 1853ter-BRCA1 mutant's inability to interact in the yeast two hybrid assay was not due to lack of protein expression, the wild type carboxy-terminal segment of BRCA1 (GSTwt-BRCA1) and mutant 1853ter segment (GST-mu-BRCA1), were prepared as GST fusions for testing in vitro. Amino acid residues 312 ± 712 of protein CtIP, identi®ed as the region that interacts with BRCA1 in the yeast two-hybrid assay, was radiolabeled and used as the target for the binding assays. Radiolabeled CtIP protein was incubated with non-recombinant GST, GST-wt-BRCA1 and GST-mu-BRCA1. As shown in Figure 2a , the radiolabeled CtIP protein was found to interact with the GST-wt-BRCA1, but not to GST-mu-BRCA1 or non-recombinant GST. We also performed additional binding experiments in which the CtIP protein prepared as GST fusions were reacted with full length radiolabeled BRCA1. Two segments of the protein CtIP, amino acid residues 324 ± 584 (GSTCtIPa) and 324 ± 697 (GST-CtIPb) were expressed as GST fusions. The wild type full length BRCA1 bound speci®cally to both GST-CtIP fusions in the in vitro binding assays (Figure 2b) . Hence, the region of CtIP from amino acid residues 324 ± 584 is the smallest segment de®ned so far for the interaction with BRCA1. As a negative control, the radiolabeled b-galactosidase was analysed under the same set of in vitro binding conditions. It was not signi®cantly retained by nonrecombinant GST or any of the GST fusion proteins (Figure 2a and b) .
Mutation screening of CtIP cDNA
Genes that are involved in neoplastic transformation have been observed to be mutated in certain tumor cell lines. We investigated if CtIP is aberrant in tumor cells by screening 89 tumor cell lines derived from dierent tissue types for homozygous deletions and coding mutations in the gene. Using two STSs that speci®cally ampli®ed dierent regions of the CtIP gene from genomic DNA, no homozygous deletions were detected in this set of 89 tumor cell lines (data not shown). However, a PCR and dye-primer sequencing based screen of CtIP cDNAs revealed ®ve missense and 11 silent variants in the coding region of the gene (Table 2) . Of interest, the BxPC3 pancreatic carcinoma cell line exhibited a A1009G change which is predicted to cause a non-conservative lysine to glutamic acid substitution at codon 337. In these BxPC3 cells, the wild-type allele of the CtIP gene was not observed; this could either be a consequence of loss of heterozygosity or non-expression. Four other missense alterations, found in cell line HCT-15, LS174T and MDA-MB134VI, were observed as heterozygotes. In the colon cell line HCT-15, the two alterations were G1180A (Val?Met) and C1306T (Pro?Ser). In another colon cell line, LS174T, a tyrosine residue was converted to serine due to the A2456G change. Two of the tumor cell lines, ovarian NIH-ovcar3 and breast MDA-MB-134VI, showed the same G1766A alteration, predicted to cause a conservative arginine to histidine substitution. The silent G2115A variant, present in 11 of the 89 tumor cell lines, appears to be a common polymorphism within the coding sequence of CtIP.
Discussion
Using the yeast two-hybrid assay, we identi®ed a protein, CtIP, that interacts with the highly conserved carboxy-terminal region of BRCA1. By in vitro biochemical assays, we demonstrated that the physical association between BRCA1 and CtIP is direct and does not appear to require other factors. Interestingly, this protein-protein interaction was disrupted when the 11 amino acids at the carboxy-terminus of BRCA1 were deleted. This premature termination of the BRCA1 protein is caused by the truncation mutation, Y1853ter, that is found in several patients with familial breast cancer (Shattuck-Eiden et al., 1995) . Additionally, we have identi®ed a number of missense variants in CtIP from a panel of 89 tumor cell lines.
Of the BRCA1 interacting proteins that have been identi®ed and characterized to date, CtIP is the only protein that binds to the BRCA1 carboxy-terminus. Several lines of evidence support the idea that this Figure 2 In vitro binding of BRCA1 to CtIP. Similar amounts of GST and GST-fusion proteins immobilized on glutathioneSepharose beads (100 ml) were incubated with 15 ml of in vitro translated proteins radiolabeled with 35 S-methionine. (a) Wild type and mutant BRCA1 carboxy-terminal segments expressed as GST fusions (GST-wt-BRCA1 and GST-mu-BRCA1) were incubated with radiolabeled CtIP protein (residues 312 ± 712), and b-galactosidase. (b) Two dierent segments of protein CtIP expressed as GST fusions (GST-CtIPa and GST-CtIPb) were incubated with radiolabeled BRCA1 and b-galactosidase. In both a and b, non-recombinant GST were reacted with all radiolabeled proteins. After washing four times with buer, the beads were resuspended in 30 ml of 26SDS ± PAGE loading dye, boiled and spun. Twenty ml of the supernatant was resolved by SDS ± PAGE. The input radiolabeled protein in each panel represents the control sample before incubation with GST or GST-fusions. Molecular weight markers are as indicated This silent sequence variant is probably a polymorphism because it was observed as a heterozygote or a non-heterozygote in 6/89 and 5/89 tumor cell lines respectively (Koonin et al., 1996; Callebaut and Mornon, 1997) . Second, many of the familial BRCA1 mutations are protein truncation lesions including a truncation that removes only the last 11 amino acids of the carboxy-terminus. A recent study has shown that truncation mutations at the conserved carboxyterminal region of BRCA1 is correlated with highly proliferative hereditary breast cancer (Sobol et al., 1996) . Lastly, as demonstrated in our yeast two-hybrid and in vitro biochemical assays, the binding of CtIP to BRCA1 was disrupted by a familial mutation, Y1853ter, at the carboxy-terminus. It is therefore plausible that the high proliferation rate of breast tumors may be related to defects caused by the loss of BRCA1-CtIP interaction.
To address the functional role of a BRCA1-CtIP interaction, it is important to understand the biological relevance of the CtIP protein. While this manuscript was in preparation, Schaeper et al. (1998) reported that CtIP interacts with another cellular protein CtBP, which has previously been implicated in the E1A pathway (Boyd et al., 1993; Schaeper et al., 1995) . Indirect evidence has indicated that CtBP may modulate the metastatic potential of the adenoviral E1A protein (Boyd et al., 1993; Schaeper et al., 1995; Sollerbrant et al., 1996) . This modulation activity of CtBP may be exerted through transcriptional regulation since the Drosophila homolog of CtBP has recently been shown to function as a short-range transcriptional repressor (Nibu et al., 1998; Poortinga et al., 1998) . The direct associations of CtIP with CtBP and BRCA1 suggest that CtIP participates in some aspects of transcriptional regulation either in the E1A or BRCA1 pathway. E1A is known to activate the expression of genes encoding cyclin A and E and phosphatase CDC25A, which are all essential mediators of G1-S transition (Pidder, 1996) . Deregulation of these cell cycle genes is a mechanism by which the E1A viral oncogene induces transformation of mammalian cells. On the other hand, the tumor suppressor BRCA1 can transactivate the expression of the cyclin-dependent kinase inhibitor p21 which blocks cell cycle progression into the S-phase (Somasundaram et al., 1997) . It would seem that potential formation of a BRCA1-CtIP-CtBP complex might somehow account for the tumor suppressive activity of BRCA1 while a CtIP-CtBP-E1A complex might contribute to the oncogenic potential of the E1A protein. The perturbation of these complexes could be an important step in the establishment of malignancy. Ouchi et al. (1998) reported that BRCA1 can stimulate genomic promoter constructs containing p53 responsive elements. It appears that the C-terminus of BRCA1 is necessary for transactivation of these elements. This is not a surprising observation since it has been demonstrated that the critical site of interaction with RNA polymerase holoenzyme is at the C-terminus of BRCA1 (Scully et al., 1997c) . It is interesting to point out that the C-terminal truncation mutation, Y1853ter, aects not only BRCA1 transcriptional activation function, but also binding with CtIP.
Perhaps CtIP plays a role in the formation of the BRCA1-RNA polymerase holoenzyme complex and in turn aects transcriptional activation.
A current view on the function of BRCA1 is that it is involved in recombination and repair through the RAD51 pathway (Scully et al., 1997b) . One may extend this possibility to include a mechanism by which DNA repair is coupled to transcription and that these processes may be monitored by the cell cycle checkpoint regulator p53. This idea is supported by biochemical studies that reveal protein-protein associations of BRCA1 and p53 with RAD51 (Sturzbecher et al., 1996; Scully et al., 1997b) , BRCA1 with p53 , BRCA1 and RAD51 with RNA polymerase holoenzyme complex (Maldonado et al., 1996; Scully et al., 1997c) . It will be of interest to determine whether CtIP participates in these processes. Based on Northern analysis, the expression pattern of CtIP is similar to that of BRCA1 and RAD51 (Miki et al., 1994; Shinohara et al., 1993) , with a high level of expression observed in testis and thymus where recombination and repair of double strand breaks occur frequently.
Mutation pro®ling of the CtIP gene in a panel of 89 tumor cell line cDNAs revealed ®ve missense sequence variants in lines derived from breast, pancreas, colon, and ovarian carcinomas. Of interest, the BxPC3 pancreatic carcinoma cell line harbored a missense alteration that is predicted to convert the basic lysine at residue 337 of CtIP to glutamic acid. Since this amino acid alteration in CtIP is rare, being observed in only one of 89 tumor cell lines, it is likely that this genetic variant re¯ects hemizygosity (i.e. LOH) or nonexpression of the wild type allele, but not homozygosity. If this non-conservative substitution is deleterious, then BxPC3 does not express functional CtIP. We investigated the possiblity that the missense variant at residue 337 might interfere with binding to BRCA1 by performing a GST pull down assay. We did not observe abrogation of the BRCA1-CtIP interaction, though we could not rule out the possibility that it could reduce binding anity (data not shown). It is conceivable that this mutation aects functions other than the BRCA1-CtIP interaction. The possibility that the CtIP gene may encode a tumor suppressor warrants further investigation.
Materials and methods
Yeast two-hybrid assay
A BRCA1 carboxy-terminal segment from amino acid residues 1602 ± 1863 was cloned into the Gal4p DNAbinding domain vector pGBT.C (Bartel et al., 1996) . This construct was used to screen an EBV-transformed B-cell cDNA library prepared in an activation domain vector (Clontech Laboratories). After co-transformation into the yeast strain J692, cells were plated on yeast minimal medium lacking tryptophan, leucine, and histidine and including 25 mM 3-amino-1,2,4-triazole (Gietz et al., 1995) . After the plates were incubated for approximately 8 days at 308C, b-galactosidase activity was determined by a ®lter assay (Breeden and Naysmyth, 1985) . Positive colonies were blue in appearance. The relative strengths of bgalactosidase activities were scored as +++ (strong), + (weak), or 7 (none).
140 His + colonies were identi®ed from the B-cell library search. One of the clones designated as B112 was digested with XhoI releasing a 1.2 kb DNA; sequencing revealed that the fragment encodes amino acid residues 312 ± 712 of CtIP (accession number U72066). This fragment was subcloned into the Gal4p DNA-binding domain fusion vector, pGBT.C and Gal4p activation domain vector, pGAD.C. Similar constructs made with BRCA1 fragments from amino acid residues 1602 ± 1863 and 1602 ± 1852 were co-transformed in all pairwise combinations. All clones were con®rmed by sequencing using the dideoxy termination method (Sanger et al., 1977) .
In vitro protein-protein interaction assay
Wild type BRCA1 (amino acid residues 1604 ± 1863), 1853ter mutant BRCA1 (amino acid residues 1604 ± 1852), CtIP segment A (amino acid residues 324 ± 584) and CtIP segment B (amino acid residue 324 ± 697) were generated by PCR and subcloned as glutathione S-transferase (GST) fusions in pGEX vectors (Pharmacia). These constructs were designated as GST-wt-BRCA1, GST-mu-BRCA1, GST-CtIPa and GST-CtIPb respectively. GST-fusion proteins were synthesized in E. coli strain BL21(DE3)pLysS (Stratagene) and puri®ed by adsorption to glutathione-Sepharose beads. Full length radiolabeled BRCA1 and b-galactosidase were produced by cloning into the pCITE translation expression vector (Novagen). The B112 insert containing amino acid residues 312 ± 712 of CtIP, identi®ed as a region that interacts with BRCA1 in a yeast two-hybrid assay, were ampli®ed by PCR with the forward primer containing the T7 promoter sequence. In vitro synthesis of BRCA1, b-galactosidase and CtIP RNAs were carried out with T7 RNA polymerase (Sambrook et al., 1989) . They were then in vitro translated in the presence of [ 35 S]methionine using a rabbit reticulocyte lysate kit from Promega. The in vitro GST-anity pull down binding assay was performed by incubating the radiolabeled proteins (BRCA1, b-galactosidase, and CtIP) with non-recombinant GST and GST fusions (wild type BRCA1, mutant BRCA1, CtIP segments) bound on beads according to the protocol of Sande and Privalsky (1996) . Five mg of GST or GST fusion proteins were used in each binding assay. The protein complexes were extensively washed to eliminate non-speci®c protein interactions and released by heating to 908C in an equal volume of 26SDS ± PAGE loading buer. One half of the reaction mix on beads and the radiolabeled protein control equivalent to one quarter of the total used in each assay were analysed by SDS ± PAGE and visualized by autoradiography.
Northern blot and RACE
A multi-tissue (Clontech Laboratories) and tumor/normal breast RNA blot (Invitrogen) were hybridized with 32 Plabeled probes of CtIP and glyceraldehyde 3-phosphate dehydrogenase (G3PDH) using standard techniques (Sambrook et al., 1989) . To obtain the missing ends of CtIP cDNA, RACE was performed using the MarathonReady premade testis cDNA pools (Clontech Laboratories). The gene-speci®c primer for 5' RACE and 3' RACE were ATGATCTTGTTCACTTCAGACCCAAGAC and TCCTCTACGTCCACGTGAAAGTTTG respectively. Full length CtIP cDNA was obtained by gene amplification using normal and tumor breast cDNA pools as templates and the following primer pair: GCGAAAGA-GAAAAGCGAGCAGCCG-forward and GAGTG-CAAAATGAAAGCGCCTTATTG-reverse. The RACE products and full length cDNA were gel puri®ed and sequenced directly.
Mutation screening of CtIP
Human tumor cell lines of various cancer types were obtained from ATCC. Total RNAs prepared using the TRI Reagent (Molecular Research Center) were reversed transcribed with Superscript II (GIBCO/BRL) to generate ®rst strand cDNAs. Using these cDNA templates and the primers listed in Table 3 , nested PCR ampli®cations and dye-primer sequencing reactions were performed to screen the entire open reading frame of CtIP for alterations according to the protocol described previously by Teng et al. (1997) . Brie¯y, 1 ng of ®rst-strand cDNA was used in each 20 ml primary PCR. Three sets of primary amplicons encompassing the entire gene were generated with the following B112 primer pairs: 1A-1P, 2A-2P and 3A-3P. Each primary product was diluted 50-fold for a secondary ampli®cation with the corresponding nested primer pairs: B-Q, C-R, D-S and E-T. The ampli®ed products of the secondary reactions were subsequently subjected to dideoxy-terminator sequencing with dye-labeled M13 forward and reverse primers. Greater than 95% coverage of the CtIP coding sequence was obtained for every tumor cell line screened. All detected mutations were con®rmed by sequencing a newly ampli®ed product. Homozygous deletion searches of tumor cell line genomic DNAs were done with following primer pairs: B112-hdF100, GGCGGTATTTGACCTGTCCA and B112-hdR301, CTTGCTTAATATGCTCCACAC; B112-hdR3122, CAA-TAGAAAACTGATTTATAAATCC and B112-hdF2994, AGACGTTGAAACAGAAACAGAAG. A reaction was scored positive when the PCR product of expected size was observed.
